Featured Articles

Daiichi Sankyo Company, Limited announced its decision to develop a genetic (mRNA) vaccine for the novel corona virus infection (hereinafter, COVID-19) in Japan. In April, 2020,…
Read More...

Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced the sale of its portfolio company Corvidia Therapeutics to Novo…
Read More...

Grifols announced the start of production of its anti-SARS-CoV-2 hyperimmune immunoglobulin with specific antibodies using the plasma of people who have overcome the disease. It is the…
Read More...

The European Commission (EC) has approved Sarclisa (isatuximab) in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of adult patients with relapsed and…
Read More...

AbbVie and Jacobio Pharmaceuticals announced a global, strategic collaboration to develop and commercialize SHP2 inhibitors, which target a key node in cancer and immune cells. SHP2 …
Read More...

Roche announced the initiation of a global phase III, randomised, double-blind, multicentre study (REMDACTA) to evaluate the safety and efficacy of Actemra/RoActemra plus the…
Read More...

Almac Group has received a $288,000 grant to support a clinical study in Sub-Saharan Africa in efforts to find a treatment for Coronavirus. This was awarded from the COVID-19…
Read More...

GlaxoSmithKline plc (GSK) announced that the US Food and Drug Administration (FDA) has granted a priority review for the company’s application seeking approval of Nucala (mepolizumab)…
Read More...

Boehringer Ingelheim announced the acquisition of Northern Biologics Inc., a wholly owned subsidiary of Northern LP. By acquiring this entity, which focuses on therapeutic antibodies…
Read More...

Sorrento Therapeutics, Inc. and Mount Sinai Health System have agreed to join forces in the investigation and development of an antibody cocktail (COVI-SHIELD) to potentially treat…
Read More...

Schreiner MediPharm has developed a compact Booklet-Label for a needle protection system used in an international phase III clinical trial conducted by pharmaceutical corporation…
Read More...

AstraZeneca and the University of Oxford announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at…
Read More...

Novartis announced plans to initiate a Phase III clinical trial to study canakinumab in patients with COVID-19 pneumonia. The CAN-COVID trial will examine the efficacy of utilizing…
Read More...

Gilead Sciences, Inc. announced topline results from the open-label, Phase 3 SIMPLE trial evaluating 5-day and 10-day dosing durations of the investigational antiviral remdesivir in…
Read More...

Griffith University researchers have joined forces with scientists from Indian Immunologicals Limited (IIL), a leading vaccines manufacturing company based in Hyderabad, India to…
Read More...

Novartis announced that the US Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to Kymriah (tisagenlecleucel), for an investigational…
Read More...

Gilead Sciences, Inc. Kite, a Gilead Company, and oNKo-innate announced the companies have entered into a three-year cancer immunotherapy research collaboration to support discovery and…
Read More...

Intensity Therapeutics announced it has entered into a clinical trial collaboration agreement with Bristol Myers Squibb Company. The program will evaluate the safety and efficacy of…
Read More...

The U.S. Food and Drug Administration approved Koselugo (selumetinib) for the treatment of pediatric patients, 2 years of age and older, with neurofibromatosis type 1 (NF1), a genetic…
Read More...

Acceleron Pharma Inc. announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sotatercept for the treatment of patients with…
Read More...